Celldex Therapeutics, Inc.

CLDX

Celldex Therapeutics, Inc.

CLDX

Insider Sentiment (TTM):

Last Purchase:2024-11-11Last Sale:2025-12-04Shares Purchased (TTM):0Shares Sold (TTM):53,464

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:70,153,110Shares Outstanding:66,566,000Institutional Ownership Pct.:105.39%

Earnings Market Reaction:

Filing Date:2026-08-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	47	36	29	36	23	17	28	36	43	115	35	21
Marketable Securities Current	670	416	490	547	607	656	697	720	760	709	389	214
Accounts And Other Receivables Net Current	0	0	2	0	0	1	1	1	2	3	3	0
Prepaid Expense And Other Assets Current	7	8	14	21	18	19	21	22	8	9	5	10
Assets Current	725	459	535	604	648	694	747	779	812	835	432	246
Property Plant And Equipment Net	10	7	5	5	4	5	4	4	4	4	4	4
Operating Lease Right Of Use Asset	5	2	2	3	3	4	4	3	2	2	3	3
Intangible Assets Net Excluding Goodwill	27	27	27	27	27	27	27	27	27	27	27	27
Other Assets Noncurrent	15	15	13	9	9	10	10	10	0	0	0	0
Assets	782	511	583	648	692	739	792	823	846	869	466	280
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	15	10	1	4	2	3	3	1	4	3	3	4
Accrued Liabilities Current	44	38	47	40	28	25	34	28	19	18	22	18
Operating Lease Liability Current	2	1	2	2	2	1	1	1	2	2	2	2
Other Liabilities Current	1	1	1	1	1	2	1	1	4	4	4	4
Liabilities Current	61	51	51	46	33	32	40	32	28	26	31	28
Operating Lease Liability Noncurrent	3	0	1	1	1	2	2	2	1	0	1	1
Other Liabilities Noncurrent	3	3	4	3	3	3	3	3	3	3	4	4
Liabilities	68	55	56	50	37	36	45	37	32	30	36	34
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	2,679	2,346	2,337	2,327	2,318	2,308	2,299	2,289	2,278	2,266	1,823	1,599
Accumulated Other Comprehensive Income Loss Net Of…	1	3	4	4	3	4	3	5	2	2	3	2
Retained Earnings Accumulated Deficit	-1,966	-1,893	-1,814	-1,733	-1,666	-1,609	-1,555	-1,508	-1,466	-1,430	-1,397	-1,354
Stockholders Equity	715	456	527	598	655	703	747	786	814	839	429	247
Liabilities And Stockholders Equity	782	511	583	648	692	739	792	823	846	869	466	280
Preferred Stock Par Or Stated Value Per Share	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Preferred Stock Shares Authorized	3	3	3	3	3	3	3	3	3	3	3	3
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	297	297	297	297	297	297	297	297	297	297	297	297
Common Stock Shares Issued	79	67	67	66	66	66	66	66	66	66	56	47
Shares Outstanding	79	67	67	66	66	66	66	66	66	66	56	47

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-5.67%	5.82%	5.88%	-	-	-	-	-	-	-	-	-
2025	1.33%	3.94%	19.62%	4.10%	23.24%	25.98%	29.91%	19.14%	8.51%	0.26%	12.10%	1.69%
2024	-20.05%	-11.14%	6.99%	26.35%	1.50%	-17.61%	-0.69%	-8.11%	-13.07%	-3.30%	-9.90%	0.69%
2023	-	-	-	-11.11%	-15.09%	-30.24%	19.41%	64.43%	66.56%	-12.94%	-21.25%	-20.78%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	11.82	8.92	10.49	13.01	19.67	21.67	18.91	24.27	29.36	31.77	13.87	8.84
Quick Ratio	11.71	8.78	10.21	12.55	19.13	21.06	18.38	23.58	29.06	31.44	13.69	8.46
Working Capital	663.61M	407.75M	483.67M	557.87M	615.44M	661.74M	707.66M	746.75M	784.32M	809.03M	400.57M	218.10M
Leverage & Debt
Debt to Equity	0.09	0.12	0.11	0.08	0.06	0.05	0.06	0.05	0.04	0.04	0.08	0.14
Debt Ratio	0.09	0.11	0.10	0.08	0.05	0.05	0.06	0.05	0.04	0.03	0.08	0.12
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.01	0.01	0.01	0.01	0.02	0.01	0.01	0.02	0.01
Per Share Metrics
Diluted EPS TTM	-3.86	-4.26	-3.90	-3.38	-3.01	-2.69	-2.45	-2.32	-2.28	-2.46	-2.92	-2.64
Free Cash Flow Per Share TTM	-3.11	-3.40	-3.22	-2.74	-2.84	-2.61	-2.48	-2.41	-1.86	-2.05	-2.25	-2.07
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-207,534.39%	-35,729.83%	-18,599.81%	-6,367.79%	-4,053.69%	-2,873.52%	-2,778.89%	-1,871.27%	-2,117.45%	-2,679.17%	-2,245.27%	-3,088.20%
Net Profit Margin TTM	-191,432.48%	-32,791.45%	-16,748.03%	-5,579.82%	-3,446.88%	-2,366.07%	-2,248.76%	-1,544.48%	-1,809.40%	-2,385.97%	-2,054.76%	-2,854.75%
Growth Metrics
Net Revenue Growth (1Y)	-97.29%	-88.56%	-77.99%	-59.66%	-30.25%	24.49%	1.99%	128.55%	155.05%	92.76%	192.02%	305.29%
Net Income Growth (1Y)	50.57%	58.59%	63.91%	45.73%	32.88%	23.45%	11.62%	23.65%	32.78%	22.12%	25.91%	17.57%
EPS Growth (1Y)	28.42%	58.16%	58.91%	45.45%	32.13%	9.48%	-16.02%	-11.85%	-4.97%	-2.06%	21.85%	16.71%
Valuation Metrics
P/E TTM	-9.64	-7.44	-6.97	-7.65	-6.77	-6.74	-10.31	-14.62	-16.27	-17.05	-13.59	-10.44
P/B TTM	4.05	4.63	3.42	2.87	2.06	1.71	2.18	2.87	3.00	2.95	4.48	5.27
P/S TTM	18,448.58	2,441.01	1,167.65	427.01	233.31	159.39	231.80	225.88	294.31	406.92	279.16	297.97
Market Cap	2.90B	2.11B	1.80B	1.72B	1.35B	1.20B	1.63B	2.25B	2.44B	2.47B	1.92B	1.30B
Enterprise Value	2.85B	2.08B	1.78B	1.68B	1.33B	1.19B	1.60B	2.22B	2.40B	2.36B	1.89B	1.28B
Calculated Values
Free Cash Flow TTM	-242.11M	-226.25M	-213.66M	-181.67M	-188.48M	-173.35M	-159.70M	-159.66M	-122.93M	-120.94M	-109.11M	-97.91M
Net Debt	-47.45M	-35.73M	-28.87M	-36.04M	-23.04M	-17.14M	-28.36M	-36.40M	-42.74M	-115.08M	-34.81M	-21.13M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2025-12-04Sale

Owner: Jimenez, Freddy A.

Title: SVP & GENERAL COUNSEL

Shares: 4,166

Price/Share: $29.10

Value: $121,230.60

Shares Owned: 30,796

Relationship: Officer

Ownership: Direct

2025-11-13Sale

Owner: Wright, Richard M.

Title: -

Shares: 49,298

Price/Share: $24.00

Value: $1,183,152.00

Shares Owned: 20,833

Relationship: Other

Ownership: Direct

2025-08-13Sale

Owner: Jimenez, Freddy A.

Title: SVP & GENERAL COUNSEL

Shares: 771

Price/Share: $24.68

Value: $19,028.28

Shares Owned: 34,962

Relationship: Officer

Ownership: Direct

2024-11-11Purchase

Owner: Marucci, Anthony S

Title: PRESIDENT & CEO

Shares: 11,500

Price/Share: $26.82

Value: $308,430.00

Shares Owned: 40,284

Relationship: Director,Officer

Ownership: Direct

2024-06-14Sale

Owner: Crowley, Elizabeth

Title: SR. VP & CPDO

Shares: 30,000

Price/Share: $34.87

Value: $1,046,100.00

Shares Owned: 9,074

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2025-12-04	Jimenez, Freddy A.	Officer	SVP & GENERAL COUNSEL	Direct	Sale	4,166	29.10	$121,230.60	30,796	4
2025-11-13	Wright, Richard M.	Other	-	Direct	Sale	49,298	24.00	$1,183,152.00	20,833	4
2025-08-13	Jimenez, Freddy A.	Officer	SVP & GENERAL COUNSEL	Direct	Sale	771	24.68	$19,028.28	34,962	4
2024-11-11	Marucci, Anthony S	Director,Officer	PRESIDENT & CEO	Direct	Purchase	11,500	26.82	$308,430.00	40,284	4
2024-06-14	Crowley, Elizabeth	Officer	SR. VP & CPDO	Direct	Sale	30,000	34.87	$1,046,100.00	9,074	4
2024-06-14	Martin, Samuel Bates	Officer	SVP AND CFO	Direct	Sale	17,172	35.42	$608,232.24	28,125	4
2024-06-07	Crowley, Elizabeth	Officer	SR. VP & CPDO	Direct	Sale	15,000	35.06	$525,900.00	9,074	4
2024-06-07	Young, Diane C.	Officer	SVP, CHIEF MEDICAL OFFICER	Direct	Sale	45,000	35.26	$1,586,700.00	2,115	4
2024-06-03	Jimenez, Freddy A.	Officer	SVP & GENERAL COUNSEL	Direct	Sale	8,006	33.60	$269,001.60	25,924	4
2024-06-03	Heath-Chiozzi, Margo	Officer	SVP OF REGULATORY AFFAIRS	Direct	Sale	58,369	33.65	$1,964,116.85	13,383	4
2024-06-03	Wright, Richard M.	Officer	SR. VP & CCO	Direct	Sale	46,844	33.76	$1,581,453.44	20,833	4
2024-05-30	Cavanaugh, Sarah	Officer	SVP OF CORP AFFAIRS & ADMIN.	Direct	Sale	20,853	33.73	$703,371.69	1,860	4
2024-05-30	Heath-Chiozzi, Margo	Officer	SVP OF REGULATORY AFFAIRS	Direct	Sale	38,719	34.07	$1,319,156.33	7,094	4
2024-05-30	Crowley, Elizabeth	Officer	SR. VP & CPDO	Direct	Sale	38,597	33.64	$1,298,403.08	9,074	4
2024-05-30	Martin, Samuel Bates	Officer	SVP AND CFO	Direct	Sale	35,000	34.05	$1,191,750.00	25,128	4
2022-12-07	Keler, Tibor	Officer	EXECUTIVE VP & CSO	Direct	Sale	16,860	36.93	$622,639.80	7,357	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

105.39%

Inst. Shares: 70,153,110

Shares Outstanding: 66,566,000

2025-12-31

106.76%

Inst. Shares: 70,911,142

Shares Outstanding: 66,422,000

2025-09-30

102.40%

Inst. Shares: 68,011,748

Shares Outstanding: 66,420,000

2025-06-30

102.73%

Inst. Shares: 68,204,522

Shares Outstanding: 66,392,000

2025-03-31

104.98%

Inst. Shares: 69,687,691

Shares Outstanding: 66,383,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	70,153,110	66,566,000	105.39%
2025-12-31	70,911,142	66,422,000	106.76%
2025-09-30	68,011,748	66,420,000	102.40%
2025-06-30	68,204,522	66,392,000	102.73%
2025-03-31	69,687,691	66,383,000	104.98%
2024-12-31	67,966,847	64,395,000	105.55%
2024-09-30	66,841,946	66,294,000	100.83%
2024-06-30	66,092,626	66,019,000	100.11%
2024-03-31	65,533,937	58,871,000	111.32%
2023-12-31	60,216,328	48,449,000	124.29%
2023-09-30	49,650,608	47,261,000	105.06%
2023-06-30	49,489,617	47,253,000	104.73%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Celldex Therapeutics, Inc. (CLDX) — SEC Financial Statements & Analysis

Celldex Therapeutics, Inc. (CLDX) is a in vitro & in vivo diagnostic substances company, incorporated in DE. Celldex Therapeutics, Inc. trades on Nasdaq as: CLDX. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Celldex Therapeutics, Inc. reported a -97.29% year-over-year revenue growth, a Debt-to-Equity ratio of 0.09x, a Price-to-Sales (P/S) ratio of 18448.58x (TTM), a Price-to-Book (P/B) ratio of 4.05x (TTM), at a market cap of $2.90B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -97.29%
Debt To Equity: 0.09x
P/S TTM: 18448.58x
P/B TTM: 4.05x
Market Cap: $2.90B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Celldex Therapeutics, Inc. in?

Celldex Therapeutics, Inc. (CLDX) operates in the In Vitro & In Vivo Diagnostic Substances industry.

What is CLDX's market cap?

Celldex Therapeutics, Inc. (CLDX) has a market capitalization of $2.90B as of 2026-06-30.

What exchange does CLDX trade on?

Celldex Therapeutics, Inc. (CLDX) trades on the Nasdaq.

Where is Celldex Therapeutics, Inc. incorporated?

Celldex Therapeutics, Inc. is incorporated in DE.